Sparks commentary

Healthcare

Sparks

FDA approves Soleno Therapeutics’ (Nasdaq: SLN) Vykat XR
Published by Arron Aatkar, PhD

The US FDA has today approved Soleno Therapeutics’ Vykat XR (diazoxide choline) extended-release tablets. This marks the first FDA approved treatment to address hyperphagia in Prader-Willi syndrome, a rare neurodevelopmental condition (caused by a genetic abnormality) estimated to afflict one in every 15,000 babies in the US each year.

Latest